March 14 Sanofi:
* Sanofi says UK's Medicines & Healthcare Products
Regulatory Agency (MHRA) has granted dupilumab, a product which
treats for atopic dermatitis (AD), a positive scientific opinion
through the Early Access to Medicines Scheme (EAMS).
* The decision means that eligible adults with severe atopic
dermatitis can access dupilumab before the drug is granted
marketing authorisation in the UK, Sanofi adds in statement
* Dupilumab is currently under joint development with
Regeneron and Sanofi and its safety and efficacy have not been
fully evaluated by any regulatory body. The formal EU regulatory
application for dupilumab is currently under review by the
European Medicines Agency (EMA).
Source text for Eikon: